BOT 0.00% 33.0¢ botanix pharmaceuticals ltd

Acne Phase 2 - Probability of Success and Likely Market Response, page-3

  1. 1,562 Posts.
    lightbulb Created with Sketch. 327
    An interesting report:

    https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-changing-landscape-of-research-and-development.pdf?_=1562887649311

    With topical treatments working from a base 50% success rate for Phase 2 trials (@Jalaluddin if I remeber correctly you've posted some info on this over the last several months?), and considering the indications we've received so far, BOT remains a compelling investment at these levels given the magnitude of the markets we will be involved in.

    Also worth noting that when using composite success rates for clinical phases, they include areas such as oncology, which form a large number of trials with a far below average success rate, effectively dragging down the composite rate significantly.

    https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-changing-landscape-of-research-and-development.pdf?_=1562887649311

    "Despite the accounting for almost 30% of the R&D product pipeline in 2018, composite success rates for oncology are only 8%.."

    https://hotcopper.com.au/data/attachments/1635/1635744-13f907bd5661f49b73b3814825852107.jpg


    "Phase II oncology drugs have about a 25% chance of making it on to the last phase. The general oncology Phase III success rate is 40%."

    https://seekingalpha.com/article/4051661-investors-guide-clinical-trials-phase-success-rates-introductory-pipeline-analysis



    Interesting to also see the rate and size of increase of big pharma:

    https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-changing-landscape-of-research-and-development.pdf?_=1562887649311

    https://hotcopper.com.au/data/attachments/1635/1635679-fc33012a1a412722bb6f471eab61c118.jpg

    Given we have at least 5 pillars (Matt hinting at more to come..):

    • Acne;
    • Atopic Dermatitis;
    • Psoriasis;
    • Antimicrobial; and
    • Permatrex.

    with each of the first 4 having multi-billion dollar markets, the above is of significant interest when considering the next few months of BOT's development.

    And Vinnie on board with his track record of multi billion dollar sales of R&D companies like BOT.

    Everything lining up nicely..



 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
33.0¢
Change
0.000(0.00%)
Mkt cap ! $519.7M
Open High Low Value Volume
34.5¢ 35.5¢ 33.0¢ $4.907M 14.27M

Buyers (Bids)

No. Vol. Price($)
33 592847 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
34.0¢ 307941 5
View Market Depth
Last trade - 16.10pm 17/06/2024 (20 minute delay) ?
Last
33.5¢
  Change
0.000 ( 2.35 %)
Open High Low Volume
34.5¢ 35.3¢ 33.3¢ 7383812
Last updated 15.59pm 17/06/2024 ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.